Table 1.
Characteristic of eligible patients (n = 550)a
| Valueb | |
|---|---|
| Age, mean ± SD years | 52 ± 15.2 |
| Female | 400 (75.3) |
| Diagnoses | |
| RA | 155 (29.7) |
| SLE | 100 (19.2) |
| Scleroderma | 51 (9.8) |
| Psoriatic arthritis | 47 (9.0) |
| Spondyloarthritis | 21 (4.0) |
| Vasculitis | 31 (5.9) |
| RA/SLE overlap | 17 (3.3) |
| Other (inflammatory)c | 80 (15.3) |
| Other (noninflammatory)d | 20 (3.8) |
| No diagnosis or missing | 28 (5.1) |
| Disease duration, median (IQR) years | 6 (3.0–14.0) |
| Disease control, median (IQR) years (range 0–100) | 77 (53.0–93.0) |
| Medications | |
| Prednisolone, median 1 (IQR 0–1) mg | 147 (26.7) |
| csDMARDs | 349 (63.8) |
| Methotrexate | 165 (30) |
| Hydroxychloroquine | 203 (36.9) |
| Sulfasalazine | 25 (4.5) |
| Mycophenolate | 50 (9.1) |
| Azathioprine | 28 (5.1) |
| Leflunomide | 16 (2.9) |
| Others (tacrolimus, cyclosporin) | 5 (1.0) |
| Cyclophosphamide | 2 (0.4) |
| bDMARDs or tsDMARDs | 98 (17.8) |
| TNF inhibitors | 53 (9.6) |
| Rituximab | 12 (2.2) |
| Secukinumab | 11 (2) |
| Tocilizumab | 9 (1.6) |
| JAK inhibitor | 6 (1.1) |
| Abatacept | 4 (0.7) |
| Ustekinumab | 3 (0.5) |
| NSAIDs | 123 (22.4) |
| No medications | 104 (19.8) |
Values are the number (%) of patients unless indicated otherwise. RA = rheumatoid arthritis; SLE = systemic lupus erythematosus; IQR = interquartile range; csDMARDs = conventional synthetic disease‐modifying antirheumatic drugs; bDMARDs = biologic DMARDs; tsDMARDs = targeted synthetic DMARDs; TNF = tumor necrosis factor; NSAIDs = nonsteroidal antiinflammatory drugs.
Data missing for age (n = 22), sex (n = 19), disease duration (n = 27), disease control (n = 15), medications (n = 24), and diagnosis (n = 28).
Other inflammatory diseases include mixed/undifferentiated connective tissue disease, sarcoidosis, IgG4‐related disease, seronegative or palindromic arthritis, Sjögren's syndrome, adult‐onset Still’s disease, juvenile idiopathic arthritis, reactive arthritis, Behçet's disease, inflammatory myopathies, relapsing polychondritis, polymyalgia rheumatica, gout, eosinophilic fasciitis, autoimmune liver disease, immune‐mediated pericarditis.
Noninflammatory diseases include fibromyalgia, osteoarthritis, and tendinopathies.